AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03903809
Drug: ESPO
RxNorm normalized name: Espotabs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
Trial: NCT01607307
Drug: Oral/enteral placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Trial: NCT02338193
Drug: DAPA/MET XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
Trial: NCT02338193
Drug: DAPA
RxNorm normalized name: Sedapap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dapagliflozin QD for 20-24 weeks
Trial: NCT01437943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 1 tablet (0 mg) daily for 180 days.
Trial: NCT02310347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03418090
Drug: 129Xe MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of pulmonary function
Trial: NCT02854592
Drug: rtPA
RxNorm normalized name: Sportpac Coldpac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous thrombolysis with rtPa
Trial: NCT00016172
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02650479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 hour IV infusion.
Trial: NCT00230074
Drug: TCH346
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02654860
Drug: Paracetamol 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
Trial: NCT02654860
Drug: Placebo injection containing Saline solution 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
Trial: NCT02036775
Drug: Lasolvan tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Lasolvan tablet 30 mg twice daily for 5 days.
Trial: NCT02036775
Drug: Lasolvan prolonged-released capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Trial: NCT02036775
Drug: Lasolvan effervescent tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Trial: NCT00581087
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA : 200 mg/day hard gelatine capsule
Trial: NCT00581087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment : 200 mg/day hard gelatine capsule
Trial: NCT02553083
Drug: doxycycline 200 mg
RxNorm normalized name: doxycycline 200 MG
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 200 mg twice daily for 14 days
Trial: NCT02553083
Drug: clarythromicin 500 mg
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarythromicin 500 mg twice a day for 10 days
Trial: NCT00694746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
Trial: NCT01321463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet once daily for 12 weeks
Trial: NCT02828241
Drug: DFD-04 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03040323
Drug: Lumason 60.7Mg Powder for Injection
RxNorm normalized name: Lumason 60.7mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
Trial: NCT03040323
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos injected prior to ultrasound-guided biopsy
Trial: NCT03365011
Drug: Placebo gas for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
Trial: NCT01674127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01193127
Drug: OMS302 Anti-inflammatory Solution
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01193127
Drug: Balanced Salt Solution (BSS) Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01682616
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
Trial: NCT00746720
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
Trial: NCT00746720
Drug: Placebo for Etoricoxib 60 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet (orally), two tablets once daily, on day one post surgery
Trial: NCT00746720
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
Trial: NCT00746720
Drug: Placebo for Etoricoxib 60 mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
Trial: NCT00104260
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03543774
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
Trial: NCT03543774
Drug: Ezetimibe/simvastatin 10/20 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
Trial: NCT04748523
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
Trial: NCT01080664
Drug: AS703569
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops
Trial: NCT01080664
Drug: AS703569
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Trial: NCT00658021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection, twice a day
Trial: NCT03543774
Drug: Ezetimibe/simvastatin 10/40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
Trial: NCT00416702
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03349008
Drug: Diammonium Glycyrrhizinate
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
Trial: NCT03349008
Drug: Diammonium Glycyrrhizinate Placebo
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Trial: NCT01008982
Drug: LimphoStat-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
Trial: NCT00309894
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01540773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Trial: NCT00003638
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03613727
Drug: Intravenous (IV) and oral Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180
Trial: NCT05944380
Drug: 0,9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.9% normal saline will be injected for the PENG block
Trial: NCT00517127
Drug: Hydroxyethylstarch 6% 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
Trial: NCT03463473
Drug: 3 mg/kg Q3W MSB2311 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion with concentration from 3 mg/kg (Q3W)
Trial: NCT03463473
Drug: 10 mg/kg Q3W MSB2311 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion with concentration from 10 mg/kg (Q3W)
Trial: NCT03463473
Drug: 20 mg/kg Q3W MSB2311 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion with concentration from 20 mg/kg (Q3W)
Trial: NCT03463473
Drug: 10 mg/kg Q2W MSB2311 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion with concentration from 10 mg/kg (Q2W)
Trial: NCT01104779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Trial: NCT00119002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg placebo
Trial: NCT02537366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216513
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline IV for 4 hours for 5 consecutive days
Trial: NCT02044406
Drug: BI 1181181, T1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, fed
Trial: NCT03760003
Drug: ABX464 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
Trial: NCT03760003
Drug: ABX464 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
Trial: NCT03760003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules of placebo once daily for 16 weeks
Trial: NCT00605761
Drug: SB656933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg treatment
Trial: NCT00605761
Drug: SB656933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg treatment
Trial: NCT03849183
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Trial: NCT00090363
Drug: ZD4054 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oral tablet once daily
Trial: NCT00090363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00090363
Drug: ZD4054 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg oral tablet once daily
Trial: NCT00228514
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01523457
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.
Trial: NCT03673657
Drug: Weekly DP chemotherapy concurrent with thoracic radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
Trial: NCT01752543
Drug: Placebo (Dextrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
Trial: NCT02932306
Drug: IDP-121 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
Trial: NCT02932306
Drug: IDP-121 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Trial: NCT02585934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, oral, pill manufactured to match RVT-101 35 mg tablet
Trial: NCT03612557
Drug: penicillin G benzathine
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 million units (IM) of benzathine benzylpenicillin
Trial: NCT03557424
Drug: Polyglucosamine Glucomannan normal dose (Verum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Trial: NCT03557424
Drug: Polyglucosamine Glucomannan high dose (Verum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Trial: NCT03557424
Drug: Placebo Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Trial: NCT02674906
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use of heparin as anticoagulant after blood salvage during cardiac surgery
Trial: NCT00893737
Drug: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
Trial: NCT00928707
Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
Trial: NCT01996683
Drug: desferal, ferriprox, blood transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation
Trial: NCT00357123
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg 10 days daily since abdominal sepsis diagnosis
Trial: NCT01906450
Drug: Scaling and root planing plus Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
Trial: NCT01906450
Drug: Scaling and root planing plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
Trial: NCT03584724
Drug: Norflo Oro
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norflo Oro is highly bioavailable curcumin complexed into phytosomes
Trial: NCT03584724
Drug: Placebo for Norflo Oro
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
Trial: NCT02988024
Drug: LY03005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03005
Trial: NCT02344719
Drug: Taurin 6g per day per oral for 28 days
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurin 6g per day per oral for 28 days
Trial: NCT02344719
Drug: Placebo 6g per day per oral for 28 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Taurin 6g per day per oral for 28 days
Trial: NCT03628625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid for 3 days
Trial: NCT00459901
Drug: Erlotinib and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01381666
Drug: INS316 solution for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Trial: NCT01056042
Drug: ethinyl estradiol 30 micrograms, gestodene 75 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet orally, everyday
Trial: NCT04236323
Drug: Not used remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil is not used during operation
Trial: NCT03207867
Drug: NIR178
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days.
Trial: NCT03574948
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks placebo (2 x 1 caps per day)
Trial: NCT02528513
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
Trial: NCT04016220
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
Trial: NCT00838435
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.